TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20056180

Group type: EXPERIMENTAL
Intervention: S. sonnei conjugate (25 microg, injected IM twice, 6 weeks apart)
Number of subjects: 2799

Group type: EXPERIMENTAL
Intervention: S. flexneri 2a conjugate (25 microg, injected IM twice, 6 weeks apart)
Number of subjects: 2799

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2799
Study: 18208904

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 17074243

Group type: EXPERIMENTAL
Intervention: Carbon fiber dressing (group T)
Number of subjects: 277

Group type: COMPARATOR
Intervention: Povidone iodine gauze (group C)
Number of subjects: 277
Study: 12196364

Group type: EXPERIMENTAL
Intervention: CTC chemotherapy (high-dose cyclophosphamide, thiotepa, carboplatin)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: FEC chemotherapy (standard-dose fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy (conventional cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (non-treated stage I breast cancer patients)
Number of subjects: 152
Study: 9817289

Group type: EXPERIMENTAL
Intervention: Spitzer Uniscale (UNISCALE)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Functional Living Index‐Cancer (FLIC)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Spitzer QOL index (QLI)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Picture-face scale (PICT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: No additional tool (nothing else)
Number of subjects: 128
Study: 7650223

Group type: EXPERIMENTAL
Intervention: Draflazine 1 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Draflazine 2 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Draflazine 4 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Draflazine 6 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2566286

Group type: EXPERIMENTAL
Intervention: Nimodipine (15 micrograms/kg/h during the first 2 h, 30 micrograms/kg/h from the 3rd to the 12th h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 40
Study: 795440

Group type: EXPERIMENTAL
Intervention: D-oxazepam hemisuccinate sodium salt (100 mg i.m.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Racemic form of D-oxazepam (100 mg i.m.)
Number of subjects: 34
Study: 7012246

Group type: EXPERIMENTAL
Intervention: Intraventricular amikacin (5 mg via Rickham reservoir)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intraventricular therapy
Number of subjects: 0
Study: 31126315

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 140

Group type: COMPARATOR
Intervention: PEG 4000
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waiting-list group
Number of subjects: 140
Study: 28831839

Group type: EXPERIMENTAL
Intervention: Customized sound therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Broadband noise therapy
Number of subjects: 18
Study: 27548054

Group type: EXPERIMENTAL
Intervention: LR3 plus KI3 acupoints
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: LR3 plus sham acupoint
Number of subjects: 57

Group type: COMPARATOR
Intervention: LR3 alone
Number of subjects: 57
Study: 24253956

Group type: EXPERIMENTAL
Intervention: Monoaxial locking technique
Number of subjects: 124

Group type: COMPARATOR
Intervention: Polyaxial locking technique
Number of subjects: 124
Study: 21990511

Group type: EXPERIMENTAL
Intervention: Standard care plus self‐selected music via overhead stereo system
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study: 19893125

Group type: EXPERIMENTAL
Intervention: Intranasal electrophoresis of vanadium
Number of subjects: 67
Study: 17950088

Group type: EXPERIMENTAL
Intervention: Younger patients (<=30 years)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Older patients (>30 years)
Number of subjects: 315
Study: 15096905

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg per day
Number of subjects: 65
Study: 11966786

Group type: EXPERIMENTAL
Intervention: Mucopolysaccharide-cartilage complex (MCC) healing ointment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Aquaphor ointment
Number of subjects: 19
Study: 9816562

Group type: EXPERIMENTAL
Intervention: Sensitivity Day simulation activity
Number of subjects: 77

Group type: COMPARATOR
Intervention: Presimulation attitude scores
Number of subjects: 77
Study: 7666251

Group type: EXPERIMENTAL
Intervention: Wheat bread-based diet (daily intake 274 g starch, 2.4 g enzyme-resistant starch, 14.4 g total dietary fiber)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oat bran-based diet (daily intake 243 g starch, 2.7 g enzyme-resistant starch, 40.2 g total dietary fiber)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both diets
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Oat bran-based diet
Number of subjects: 9
Study: 2711724

Group type: EXPERIMENTAL
Intervention: Intracervical Prostaglandin E2 (PGE2) gel application within 6 hours after PROM
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Intracervical Prostaglandin E2 (PGE2) gel application within 7-12 hours after PROM
Number of subjects: 416

Group type: COMPARATOR
Intervention: Oxytocin infusion after 12 hours of waiting
Number of subjects: 416

Group type: COMPARATOR
Intervention: Waiting 12 hours for spontaneous labor
Number of subjects: 416
Study: 798636

Group type: EXPERIMENTAL
Intervention: Formalin‐inactivated cholera vaccine
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Partially purified toxoid preparation
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Whole‐cell heat‐killed cholera vaccine
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Whole‐cell heat‐killed El Tor vaccine
Number of subjects: 998

Group type: COMPARATOR
Intervention: Hypodermic syringe
Number of subjects: 998

Group type: COMPARATOR
Intervention: Jet injector
Number of subjects: 998
Study: 31709823

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31449758

Group type: EXPERIMENTAL
Intervention: Exercise intervention (EXE); 12 weeks, 4 days/week, 40-60 minutes/day at >70% HRpeak
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (CTL); maintaining usual activity
Number of subjects: 35
Study: 29078762

Group type: EXPERIMENTAL
Intervention: Structured treatment program for high fracture risk women in the intervention group, based on screening program including FRAX, DXA, and IVA.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care for the control group, with screening at the end of the trial.
Number of subjects: 0
Study: 26630467

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily for 14 days postoperatively
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Both groups (Aspirin and Control)
Number of subjects: 170
Study: 23899116

Group type: EXPERIMENTAL
Intervention: Attractive pen (intervention group)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No pen (control group)
Number of subjects: 125
Study: 21237715

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E
Number of subjects: 894

Group type: COMPARATOR
Intervention: Rabies vaccine
Number of subjects: 894
Study: 19475459

Group type: EXPERIMENTAL
Intervention: Computerized prescribing alerts alone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Computerized prescribing alerts plus group educational sessions
Number of subjects: 14

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of alert-group to usual care
Number of subjects: 14

Group type: COMPARATOR
Intervention: Comparison of alert-plus-education group to usual care
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Comparison of alert-group to alert-plus-education group
Number of subjects: 14
Study: 17325089

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin/sulbactam for 48 hours followed by oral amoxicillin/clavulanate for 7 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clindamycin for 48 hours followed by oral clindamycin for 7 days
Number of subjects: 60
Study: 15361375

Group type: EXPERIMENTAL
Intervention: Methotrexate with folate supplementation
Number of subjects: 411

Group type: COMPARATOR
Intervention: Low dose methotrexate (non-adherent group)
Number of subjects: 411

Group type: COMPARATOR
Intervention: High dose methotrexate (non-adherent group)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Adherence to guidelines
Number of subjects: 411
Study: 12047964

Group type: EXPERIMENTAL
Intervention: de Gramont regimen (folinic acid 200 mg/m(2), fluorouracil bolus 400 mg/m(2), and infusion 600 mg/m(2) on days 1 and 2, repeated every 14 days)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Lokich regimen (protracted venous infusion of fluorouracil 300 mg/m(2) daily)
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: raltitrexed (3 mg/m(2) intravenously every 21 days)
Number of subjects: 905

Group type: COMPARATOR
Intervention: raltitrexed
Number of subjects: 905

Group type: COMPARATOR
Intervention: de Gramont versus Lokich
Number of subjects: 905

Group type: COMPARATOR
Intervention: de Gramont versus raltitrexed
Number of subjects: 905
Study: 9474447

Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: High-dose ECT (2.5 x threshold)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 79

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 79
Study: 7699188

Group type: EXPERIMENTAL
Intervention: High-fat, high-energy nutrition supplement consumed at a maximum of 30% of estimated daily energy requirements
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-fat, high-energy nutrition supplement
Number of subjects: 19
Study: 2494948

Group type: EXPERIMENTAL
Intervention: MMC + HCFU
Number of subjects: 69

Group type: COMPARATOR
Intervention: MMC only
Number of subjects: 69
Study: 403767

Group type: EXPERIMENTAL
Intervention: Radiotherapy plan at M.D. Anderson Hospital and Tumor Institute (Group B)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Radiotherapy plan at University of Mississippi Medical Center (Group A)
Number of subjects: 101
Study: 30665989

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study: 29058112

Group type: EXPERIMENTAL
Intervention: Glutamine 0.25 g kg‐1 FFM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glutamine 0.5 g kg‐1 FFM
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glutamine 0.9 g kg‐1 FFM
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 25333309

Group type: EXPERIMENTAL
Intervention: Cirrhotic livers
Number of subjects: 19

Group type: COMPARATOR
Intervention: Noncirrhotic livers
Number of subjects: 19
Study: 23948846

Group type: EXPERIMENTAL
Intervention: High-power pain threshold ultrasound (HPPTUS) technique
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional ultrasound technique
Number of subjects: 41
Study: 22166329

Group type: EXPERIMENTAL
Intervention: Prebiopsy parameters including PSA, DRE, TRUS findings, and prostate volume
Number of subjects: 19950

Group type: EXPERIMENTAL
Intervention: Family history of prostate cancer
Number of subjects: 19950

Group type: EXPERIMENTAL
Intervention: Multivariate risk assessment
Number of subjects: 19950

Group type: EXPERIMENTAL
Intervention: Diagnosis of prostate cancer
Number of subjects: 19950
Study: 19680682

Group type: EXPERIMENTAL
Intervention: Bed-rest for 56 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Closed-chain simulated resistance exercises targeting lower-limb antigravity extensor muscles
Number of subjects: 10
Study: 17349882

Group type: EXPERIMENTAL
Intervention: 40 mg/day of atorvastatin
Number of subjects: 56

Group type: COMPARATOR
Intervention: 10 mg/day of ezetimibe plus 10 mg/day of atorvastatin
Number of subjects: 56
Study: 15292365

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion (250 microg/hr)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 4
Study: 14564912

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal (HC; 65 E% carbohydrates, 20 E% fat, 15 E% protein)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: High-fat meal (HF; 40 E% carbohydrates, 45 E% fat, 15 E% protein)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Isocaloric meals every four hours
Number of subjects: 7
Study: 9560042

Group type: EXPERIMENTAL
Intervention: Infant Flow Driver (IFD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Single prong nasal CPAP
Number of subjects: 20
Study: 8249558

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (70% nitrous oxide in oxygen and fentanyl)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Air (isoflurane in air/oxygen and fentanyl)
Number of subjects: 42
Study: 3622197

Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) group, 0.71 ± 0.12 g X kg‐1 X day‐1 protein for 4.5 ± 1 months
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal-protein diet (NPD) group, 1.44 ± 0.12 g X kg‐1 X day‐1 protein for 11.7 ± 7 months
Number of subjects: 16
Study: 29338326

Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PVI + CFAEs
Number of subjects: 0

Group type: COMPARATOR
Intervention: PVI
Number of subjects: 0
Study: 27009295

Group type: EXPERIMENTAL
Intervention: Traditional Resistance Training (TRT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 30
Study: 24243080

Group type: EXPERIMENTAL
Intervention: Valsalva maneuver (VM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EMLA(®) 5% cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vaseline (Control)
Number of subjects: 60
Study: 22417316

Group type: EXPERIMENTAL
Intervention: Tapas Acupressure Technique (TAT®)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Social-support group meetings (SS)
Number of subjects: 285
Study: 19815042

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplements
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 17629133

Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative bowel management
Number of subjects: 0
Study: 16204662

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) guided therapy
Number of subjects: 433

Group type: COMPARATOR
Intervention: Clinical assessment alone (Control)
Number of subjects: 433
Study: 11936390

Group type: EXPERIMENTAL
Intervention: Laster 'shark‐fin' osteotome
Number of subjects: 10

Group type: COMPARATOR
Intervention: Obwegeser osteotome
Number of subjects: 10
Study: 10396888

Group type: EXPERIMENTAL
Intervention: Interdisciplinary psychoeducational family group intervention (7 weekly, 2-hour sessions)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 94
Study: 7742756

Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, and Fractionated Total Body Irradiation
Number of subjects: 56
Study: 1539456

Group type: EXPERIMENTAL
Intervention: Acellular pertussis DTP vaccine containing 12.5 micrograms (AC-12.5)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Acellular pertussis DTP vaccine containing 25 micrograms (AC-25)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Whole-cell DTP (WC-DTP)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Acellular vaccines (AC-12.5 and AC-25)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Acellular vaccine (AC-12.5)
Number of subjects: 111
Study: 3104512

Group type: EXPERIMENTAL
Intervention: Prophylactic i.v. nitroglycerin at a dose of 0.7 microgram/kg‐1/min‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Anesthesia induced by fentanyl, flunitrazepam and pancuronium maintained with N20 and volatile anesthetics
Number of subjects: 0
Study: 31557492

Group type: EXPERIMENTAL
Intervention: PF-5190457 (GHS-R1a inverse agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30290622

Group type: EXPERIMENTAL
Intervention: Slow induction of light general anesthesia and tracheal intubation (group M)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laryngeal mask light general anesthesia (group H)
Number of subjects: 30
Study: 27132086

Group type: EXPERIMENTAL
Intervention: Add-on dTMS (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard abortive or preventive antimigraine treatment (n=7)
Number of subjects: 14
Study: 26154456

Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (SLB)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional brackets (CLB)
Number of subjects: 25
Study: 26399269

Group type: EXPERIMENTAL
Intervention: Intuitive Eating (IE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calorie Restriction (CR)
Number of subjects: 0
Study: 21601822

Group type: EXPERIMENTAL
Intervention: Fibrin sealant
Number of subjects: 56

Group type: COMPARATOR
Intervention: Suture fixation
Number of subjects: 56
Study: 18773960

Group type: EXPERIMENTAL
Intervention: CSA/MMF
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CSA/SRL
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TAC/MMF
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TAC/SRL
Number of subjects: 200
Study: 17138783

Group type: EXPERIMENTAL
Intervention: High-fidelity mannequin training
Number of subjects: 140

Group type: COMPARATOR
Intervention: Low-fidelity mannequin training
Number of subjects: 140
Study: 12648884

Group type: EXPERIMENTAL
Intervention: 2 mg oestradiol
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 1 mg oestradiol
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 10884878

Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Trimethoprim‐sulfamethoxazole (160 mg trimethoprim, 800 mg sulfamethoxazole)
Number of subjects: 780
Study: 7780671

Group type: EXPERIMENTAL
Intervention: Coils (Timor and Moon Tiger containing 0.15% W/W of esbiothrin)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Mats (ARS MATS containing d-allethrin and Moon Tiger with S biothrin and diethyl-toluamide)
Number of subjects: 1029

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1029

Group type: EXPERIMENTAL
Intervention: Mats (ARS MATS)
Number of subjects: 1029
Study: 2185962

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg, orally, twice daily for 4 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (orally, twice daily for 4 weeks)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 6996660

Group type: EXPERIMENTAL
Intervention: Oral practolol 200 mg twice daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 55
Study: 31712735

Group type: EXPERIMENTAL
Intervention: 63 early symptoms/sensations combined with 7 background factors
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Descriptors only
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Background predictors only
Number of subjects: 506
Study: 26732104

Group type: EXPERIMENTAL
Intervention: Transumbilical two-port laparoscopic varicocele ligation (TTLVL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional laparoscopic varicocele ligation (CLVL)
Number of subjects: 90
Study: 26009929

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg bid)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23439357

Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of ulinastatin and tranexamic acid
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (Physiological saline)
Number of subjects: 120
Study: 21572483

Group type: EXPERIMENTAL
Intervention: CPAP with Venturi‐like flow generator
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CPAP with Boussignac's device
Number of subjects: 20
Study: 19154840

Group type: EXPERIMENTAL
Intervention: Reducing vertical center of mass (COM) displacement during gait
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Increasing vertical center of mass (COM) displacement during gait
Number of subjects: 10
Study: 17006811

Group type: EXPERIMENTAL
Intervention: Community-associated MRSA (CA-MRSA) strains
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthcare-associated MRSA (HA-MRSA) strains
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthcare-associated infections
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: CA-MRSA infections
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison of CA-MRSA and HA-MRSA infections
Number of subjects: 37
Study: 12601217

Group type: EXPERIMENTAL
Intervention: 1.0 mol/L gadobutrol
Number of subjects: 43

Group type: COMPARATOR
Intervention: 0.5 mol/L gadobutrol
Number of subjects: 43
Study: 10672435

Group type: EXPERIMENTAL
Intervention: 3 mg of controlled‐release melatonin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9574377

Group type: EXPERIMENTAL
Intervention: Perforating appendicitis
Number of subjects: 519

Group type: COMPARATOR
Intervention: Nonperforating appendicitis
Number of subjects: 519
Study: 7952047

Group type: EXPERIMENTAL
Intervention: L-alpha-glycerophosphorylcholine (1 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2959917

Group type: EXPERIMENTAL
Intervention: Etretin 40 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Etretinate 40 mg
Number of subjects: 9
Study: 31695168

Group type: EXPERIMENTAL
Intervention: Escitalopram, Sertraline, Venlafaxine-XR (antidepressants)
Number of subjects: 163
Study: 30091952

Group type: EXPERIMENTAL
Intervention: Golimumab in combination with methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo in combination with methotrexate
Number of subjects: 0
Study: 28647668

Group type: EXPERIMENTAL
Intervention: Early improvement (Hamilton Depression Rating Scale reduction > 20% after 14 days of treatment)
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Early improvement with melancholic features
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Combined marker of early non-improvement and melancholic features
Number of subjects: 889